Explore the World ADC Conference highlights on antibody-drug conjugates and their impact on cancer therapy and clinical ...
Experimental data from FAP-Exd (AVA6103) demonstrates a more favorable profile compared to the marketed Antibody Drug Conjugate (ADC) ...
Risk Factors for Primary Bone Cancer After Childhood Cancer: A PanCare Childhood and Adolescent Cancer Survivor Care and Follow-Up Studies Nested Case-Control Study Antibody-drug conjugates (ADCs) are ...
Because of advances in linker conjugation chemistry and our understanding of the ADC mechanism of action in vivo, an increasing breadth of anticancer agents are now being incorporated in newer ADC ...
BOTHELL, Wash.--(BUSINESS WIRE)-- Immunome, Inc. (IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, recently presented preclinical data ...
What are the biggest hurdles preventing the wider adoption/utilization of ADCs? Stability and toxicity are two of the major challenges. First, linker stability issues result in the immediate release ...
Gene signatures associated with increased efficacy of micvotabart pelidotin (MICVO) due to greater linker cleavage were identified based on differential gene expression analysis of PDX ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results